Swiss drug major Roche Holding AG (RHHBY) reported Thursday that its first-quarter Group sales increased 7 percent to 15.44 billion Swiss francs from last year's 14.40 billion francs.
On a constant currency basis, sales grew 6 percent, driven by high demand for newer medicines and diagnostic solutions.
Pharmaceuticals Division sales grew 9 percent on a reported basis and 8 percent at constant currency rates from last year to 11.95 billion francs.
The results reflected continued strong demand for a broad range of medicines. Top growth drivers were Phesgo for breast cancer, Vabysmo for severe eye diseases, Xolair for allergies and Hemlibra for haemophilia A.
Diagnostics Division sales remained stable at 3.49 billion francs, with high demand across products and regions offsetting the impact of the recent healthcare pricing reforms in China.
Looking ahead, for fiscal 2025, Roche continues to expect an increase in Group sales in the mid single digit range, and core earnings per share to develop in the high single digit range, both at constant currency rates.
Roche expects to further increase its dividend in Swiss francs.
Roche CEO Thomas Schinecker said, "We are confident we will continue our positive momentum and confirm our full-year outlook."
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.